Evidence map›Paper›PMID 36164632›Full record

ArticleReports of biochemistry & molecular biology2022

Marwa Abdelgwad, Dina Sabry, Latifa Mohamed Abdelgawad, Doaa Mohamed Elroby Ali

Open access · greenAbstract read
In one paragraph

Article in Reports of biochemistry & molecular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Marwa AbdelgwadMedical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Giza, Egypt.
Dina SabryMedical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Giza, Egypt.
Latifa Mohamed AbdelgawadMedical applications of lasers Department, National Institute of Laser Enhanced Sciences (NILES), Cairo University, Giza, Egypt.
Doaa Mohamed Elroby AliBiochemistry Department, Faculty of Pharmacy, Deraya University, Minia, Egypt.
Badr University in Cairo · EGCairo University · EGDeraya University

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The clinical effect of photodynamic therapy (PDT) may be correlated with the degree of dysplasia of cancer tissues. The aim of this study was to compare the effects of cisplatin, silver nanoparticles (AgNps), and photodynamic therapy (PDT) using methylene blue (MB) photosensitizer on Head and Neck squamous cell carcinoma - cell line (HNSCC), Hep-2, through genes expression. Methods: Hep-2 cells were divided into four groups: group I as control and without any treatment, group II and III were treated by cisplatin and AgNps, respectively, and group IV were incubated with MB for four minutes followed by PDT using laser irradiation at 650 nm for 8 minutes. The resulting toxicity was assessed in cell lines using MTT cytotoxicity assay. Further, apoptosis and the response to treatment was examined via RT-qPCR. Results: MB-PDT inhibited the proliferation of Hep-2 cells. Following PDT, compared with AgNps cells and via MTT assay, a highly significant decrease was observed in cell proliferation in Cancer cells treated with AgNps and MB- PDT groups compared to cancer group cells and cancer cells treated with Cisplatin (p value< 0.001). Mechanistically, both the mRNA and protein expression levels of Discussion: MB-PDT effectively killed Hep-2 cells in vitro, however, under the same conditions, the susceptibilities of the cell line to cisplatin, AgNps, and MB-PDT were different. Further studies are necessary to confirm whether this difference is present in clinical oral cancer lesions.

Indexed as

Head and Neck squamous cell carcinoma (HNSCC)Methylene Blue (MB)photodynamic therapy (PDT)Photosensitizer (PS)silver nanoparticles (AgNps)

Identifiers

PMID36164632
PMCPMC9455178
OpenAlexW4297256728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.